25Sep, 2024 CereVasc Announces Journal of Molecular Therapy Publication Highlighting the eShunt® Platform as a CNS Gene Therapy Delivery Methodcerevasc2024-10-14T16:23:47+00:00September 25th, 2024|Press Release|Read More
17Sep, 2024 CereVasc Announces Enrollment of the 50th Patient in Pilot Studies of the eShunt® System for Normal Pressure Hydrocephaluscerevasc2024-10-14T16:19:05+00:00September 17th, 2024|Press Release|Read More
28Aug, 2024 eShunt® System Receives FDA Breakthrough Device Designationcerevasc2024-10-14T16:15:33+00:00August 28th, 2024|Press Release|Read More
16Jul, 2024 CereVasc Announces Appointments of New DirectorsAdmin2024-07-18T18:46:24+00:00July 16th, 2024|Press Release|Read More
13May, 2024 CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure HydrocephalusAdmin2024-05-28T21:41:18+00:00May 13th, 2024|Press Release|Read More
07May, 2024 CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephaluscerevasc2024-05-28T21:43:24+00:00May 7th, 2024|Press Release|Read More
